Vulnerability Monitor

The vendors, products, and vulnerabilities you care about

CVE-2017-17678

BMC Remedy Mid Tier 9.1SP3 is affected by cross-site scripting (XSS). A DOM-based cross-site scripting vulnerability was discovered in a legacy utility.

Published

2021-05-19T14:15:07.367

Last Modified

2024-11-21T03:18:26.867

Status

Modified

Source

[email protected]

Severity

CVSSv3.1: 6.1 (MEDIUM)

CVSSv2 Vector

AV:N/AC:M/Au:N/C:N/I:P/A:N

Access Vector: NETWORK
Access Complexity: MEDIUM
Authentication: NONE
Confidentiality Impact: NONE
Integrity Impact: PARTIAL
Availability Impact: NONE

Exploitability Score

8.6

Impact Score

2.9

Weaknesses

Type: Primary
CWE-79

Affected Vendors & Products

Type	Vendor	Product	Version/Range	Vulnerable?
Application	bmc	remedy_mid-tier	9.1	Yes

References

http://bmc.com Product ([email protected])
http://remedy.com Product ([email protected])
https://docs.bmc.com/docs/ars91/en/9-1-00-fixes-available-for-remedy-ar-system-security-vulnerabilities-800555806.html Release Notes, Vendor Advisory ([email protected])
https://seclists.org/fulldisclosure/2017/Oct/52 Mailing List, Third Party Advisory ([email protected])
http://bmc.com Product (af854a3a-2127-422b-91ae-364da2661108)
http://remedy.com Product (af854a3a-2127-422b-91ae-364da2661108)
https://docs.bmc.com/docs/ars91/en/9-1-00-fixes-available-for-remedy-ar-system-security-vulnerabilities-800555806.html Release Notes, Vendor Advisory (af854a3a-2127-422b-91ae-364da2661108)
https://seclists.org/fulldisclosure/2017/Oct/52 Mailing List, Third Party Advisory (af854a3a-2127-422b-91ae-364da2661108)